Day
Hour
Minute
Second

November 12-13, Boston MA

Advance clinical efficacy and commercial success of targeted cell depletion and immune tolerance technologies for Autoimmune Disease

Why Autoimmunity Partnering Summit?

More Targeted

Uniting C-level and Business Development with aligned strategic and scientific interests across tolerance and targeted cell depletion, to increase interactions with a volume of viable partners.

Earlier Opportunity

People work with people, and with partnerships often delayed by not finding and building a relationship with the right individual sooner, meet the right contacts from buyers scouting earlier pipeline opportunities, sooner.

With Scientific Insights

Evaluate competitive landscapes, assess where your research fits within the broader landscape to differentiate, and meet with synergistic researchers to share risks through collaboration with complementary projects.

Size of Networking Opportunity

Total Audience Networking

Creating Alignment Through Targeted Critical Mass: With a shared focus on scientific interests and partnering goals, attendees enjoy more meaningful interactions, free from distractions. This leads to higher-quality conversations, better engagement, and significantly improved follow-up opportunities

Interested Group Matchmaking & Speed Dating

Organized Speed Networking Icebreaker: Engage in speed networking to meet with all attending prospects F2F, to enable follow up and identify who’s who in the room.

Pharma Matchmaking Sessions: Once meetings are scheduled on the partnering app, biotech submit pharma not able to meet with them, and pharma select biotech of interest. Prioritising matchmaking interested parties together, join a rotating seating plan of pharma tables for protected networking time in small groups. Each group rotation ensures new companies meet each time.

Individual Meetings: One-on-One Partnering™

Partnering Portal: Using the same partnering portal as BIO, search attendees and pre-schedule meetings into calendars ahead of the conference, with meeting automatically linked to a private meeting space.

Why Now?

The unprecedented clinical efficacy and investment generated by Candid Therapeutics' $370M debut has positioned TCE antibodies in the race with cell therapies, as targeted B cell depletion takes on the clinical efficacy and commercial success of Humira.  

Combined with immune tolerization to rebuild a less aberrant immune system through engineered Tregs and antigen-specific immune tolerance; immune reset and reconstitution will change treatment paradigms dramatically. 

But, despite this dynamic macroenvironment, the average biotech-pharma collaboration takes over a year, and with pharma receiving >700 invitations to connect at large conferences; not meeting the right contact in person is elongating biotech deal-making.  

The Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind, laying enabled partnering on top of hyper-relevant scientific discussion so that pharma can contextualize and compare, and biotech can have guaranteed face-to-face meetings with key contacts specific to immunology deal-making. 

CAR-TCR-348-min (1)
CAR-TCR-439-min

EXPERT SPEAKERS INCLUDE

Chris Gagliardi

Chris Gagliardi

Principal

Sanofi Ventures

Nicola La Monica

Nicola La Monica

Senior Director, Strategic Search & Evaluation

Johnson & Johnson

Swarna Balasubramanian

Swarna Balasubramanian

Associate Director, Search & Evaluation Respiratory & Immunology

AstraZeneca

Melissa Matzelle

Melissa Matzelle

Director, Immunology Search & Evaluation

AbbVie

Emma Smith

Emma Smith

Head of Immune Reset

UCB

Testimonials

“This was a brilliant opportunity to connect with potential partners and hear meaningful talks and discussions relevant to the space."

“The event assembled a diverse set of stakeholders extremely relevant in ADC & RLT partnering, including pharma BD, investors, and biotech executives. It was the right size (~100 attendees) that created organic opportunities for connections”

OTHER HANSON WADE SUMMITS